Pathophysiology and treatment of lipid perturbation after cardiac transplantation

Current Opinion in Cardiology

Volumn 12, Issue 2, 1997, Pages 153-160

  Ballantyne, Christie M ^a   El Masri, Bassem ^a   Morrisett, Joel D ^a   Torre Amione, Guillermo ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PREDNISONE; SIMVASTATIN; TACROLIMUS; TRIACYLGLYCEROL;

ADVERSE DRUG REACTION; ALLOGRAFT; APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIPOPROTEIN METABOLISM; MUSCLE DISEASE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030967566     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199703000-00010     Document Type: Article

References (79)

1. Ballantyne CM, Jones PH, Payton-Ross C, Patsch W, Short HD III, Noon GP, Gotto AM Jr, DeBakey ME, Young JB: Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc 1987, 19(4 suppl 5):60-62.
2. Keogh A, Simons L, Spratt P, Esmore D, Chang V, Hickie J, Baron D: Hyperlipidemia after heart transplantation. J Heart Transplant 1988, 7:171-175.
3. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, Gotto AM Jr: Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992, 19:1315-1321.
4. Hess ML, Hastillo A, Mohanakumar T, Cowley MJ, Vetrovac G, Szentpetery S, Wolfgang TC, Lower RR: Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983, 68:II-94-II-101.
5. Eich D, Thompson JA, Ko DJ, Hastillo A, Lower R, Katz S, Katz M, Hess ML: Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991, 10:45-49.
6. Gao S-Z, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, Stinson EB: Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987, 76:V-56-V-61.
7. Cocanougher B, Ballantyne CM, Pollack MS, Payton-Ross C, Lowry R, Kleiman NS, Farmer JA, Noon GP, Short HD, Young JB: Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transplant Proc 1993, 25:233-236.
8. Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kates MA, Smart FW, Stapleton DD: Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 1995, 26:1537-1544. Hypertriglyceridemia remained a significant risk factor after stepwise logistic regression analysis for development of transplant CAD assessed by intracoronary ultrasound.
9. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT: Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987, 76:827-834.
10. McManus BM, Horley KJ, Wilson JE, Malcom GT, Kendall TJ, Miles RR, Winters GL, Costanzo MR, Miller LL, Radio SJ: Prominence of coronary arterial wall lipids in human heart allografts: implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995, 147:293-308. Pathologic examination of cardiac allografts after explant and at autopsy revealed extensive lipid deposition,
11. Jevnikar AM, Petric R, Holub BJ, Philbrick D-J, Clark WF: Effect of cyclosporine on plasma lipids and modification with dietary fish oil. Transplantation 1988, 46:722-725.
12. Schorn TF, Kliem V, Bojanovski M, Bojanovski D, Repp H, Bunzendahl H, Frei U: Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transplant Int 1991, 4:92-95.
13. Arnadottir M, Thysell H, Nilsson-Ehle P: Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: ciclosporin-versus non-ciclosporin-treated patients. Am J Nephrol 1991, 11:391-396.
14. López Miranda J, Pérez-Jiménez F, Torres A, Espmo-Montoro A, Gomez P, Hidalgo-Rojas L, Ordovas JM, Jiménez-Perepérez JA: Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992, 25:379-386.
15. Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC: Pharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characteriration of drug in lipoprotein fractions. J Pharmacol Sci 1992, 81:208-211.
16. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr, Young JB: Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989, 262:53-56.
17. Torras J, Herrero I, Castells A, Galceran JM, Fiol C, Seron D, Sabate I, Alsina J, Grinyo JM: Effect of ciclosporin on serum lipids and modification with LSL 90202, a lysine salt of eicosapentaenoic acid. Nephron 1995, 69:318-322.
18. López-Miranda J, Vilella E, Pérez-Jimënez F, Espino A, Jiménez-Perepërez JA, Masana L, Turner PR: Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 1993, 42:678-683.
19. López-Miranda J, Pérez-Jiménez F, Gómez-Gerique JA, Espino-Montoro A, Hidalgo-Rojas L, Pedreño J, Jiménez-Perepérez JA: Effect of cycloporin on plasma lipoprotein lipase activity in rats. Clin Biochem 1992, 25:387-394.
20. Superko HR, Haskell WL, Di Ricco CD: Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am J Cardiol 1990, 66:1131-1134.
21. Levy GA: Neoral therapy in liver transplantation. Transplant Proc 1996, 28:2225-2228.
22. Abouljoud MS, Levy MF, Klintmalm GB, and the US Multicenter Study Group: Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter trial. Transplant Proc 1995, 27:1121-1123.
23. Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, Mor E, Sheiner P, Miller CM: Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506s. Transplantation 1994, 57:1395-1398.
24. Swenson JM, Fricker FJ, Armitage JM: Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. J Am Coll Cardiol 1995, 25:1183-1188.
25. Mor E, Facklam D, Hasse J, Sheiner P, Emre S, Schwartz M, Miller C, for the US Multicenter FK506 Study Group: Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. Transplant Proc 1995, 27:1126.
26. Loss M, Winkler M, Schneider A, Oldhafer K, Manns MP, Pichlmayr R: Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy. Transplant Proc 1996, 28:1006-1007.
27. Renlund DG, Bristow MR, Crandall BG, Burton NA, Doty DB, Karwande SV, Gay WA Jr, Jones KW, Hegewald MG, Hagan ME, et al.: Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant 1989, 8:214-219.
28. Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, Kwiterovich PO, Pearson TA, Ettinger WH, Renlund D: Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988, 85:632-638.
29. Awni WM, Heim-Duthoy K, Kasiske BL: Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. Transplant Proc 1990, 22:1193-1196.
30. Gardier AM, Mathé D, Guédeney X, Barré J, Benvenutti C, Navarro N, Vernillet L, Loisance D, Cachera J-P, Jacotot B, Tillement J-P: Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit 1993, 15:274-280.
31. De Groen PC, Wiesner RH, Krom RAF: Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay? Transplant Proc 1988, 20:374-376.
32. Bastani B, Rittenhouse M, Garvin P: Reduced nephrotoxicity of cyclosporine A in hypercholesterolemic cadaveric renal transplant patients. Clin Transplant 1994, 8:413-415.
33. Ingulli E, Tejani A: Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol 1992, 3:254-259.
34. Keogh AM, Spratt P: Drugs in cardiac transplantation [letter]. N Engl J Med 1996, 334:402.
35. Porres FG, Stevenson WC, McCullough C, Pruett TL, Lobo PI, Nezamuddin N: Need for reduction of cyclosporin dosage in renal transplant patients with hypertriglyceridemia but not hypercholesterolemia. Transplant Int 1996, 9:164-167.
36. Nieminen MS, Mattila K, Valtonen V: Infection and inflammation as risk factors for myocardial infarction. Eur Heart J 1993, 14(suppl K):12-16.
37. Mehran M, Seidman E, Marchand R, Gurbindo C, Levy E: Tumor necrosis factor-α inhibits lipid and lipoprotein transport by Caco-2 cells. Am J Physiol 1995, 269:G953-G960.
38. Ettinger WH, Miller LA, Smith TK, Parks JS: Effect of interleukin-1 alpha on lipoprotein lipids in cynomolgus monkeys: comparison to tumor necrosis factor. Biochim Biophys Acta 1992, 1128:186-192.
39. Torre-Amione G, Kapadia S, Lee J, Durand J-B, Bies RD, Young JB, Mann DL: Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
40. Andalibi A, Liao F, Imes S, Fogelman AM, Lusis AJ: Oxidized lipoproteins influence gene expression by causing oxidative stress and activating the transcription factor NF-κB. Biochem Soc Trans 1993, 21:651-655.
41. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
42. Calderon TM, Factor SM, Hatcher VB, Berliner JA, Berman JW: An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG9: expression in vivo and in inflamed human vessels and atherosclerotic human and Watanabe rabbit vessels. Lab Invest 1994, 70:836-849.
43. Zembowicz A, Jones SL, Wu KK: Induction of cyclooxygenase-2 human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest 1995, 96:1688-1692.
44. Kume N, Gimbrone MA Jr: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994, 93:907-911.
45. Khan BV, Parthasarathy SS, Alexander RW, Medford RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995, 95:1262-1270.
46. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P: The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994, 14:1829-1836.
47. Hajjar KA, Nachman RL: The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med 1996, 47:423-442.
48. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM: Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993, 260:1655-1658.
49. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994, 370:460-462.
50. Cockerill GW, Rye K-A, Gamble JR, Vadas MA, Barter PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994. Potential protective effects of HDL in inhibiting cytokine-induced expression of cell adhesion molecules are assessed in vitro.
51. Jambou D, Dejour N, Bayer P, Poiree J-C, Fredenrich A, Issa-Sayegh M, Adjovi-Desouza M, Lapalus P, Harter M: Effect of human native low-density and high-density lipoproteins on prostaglandin production by mouse macrophage cell line P388D1: possible implications in pathogenesis of atherosclerosis. Biochim Biophys Acta 1993, 1168:115-121.
52. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M: Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891
53. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269:3015-3023.
54. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627. The first clinical trial that has demonstrated beneficial effects of lipid-lowering therapy on the development of transplant CAD and survival.
55. Cutts JL, Bankhurst AD: Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990, 145:244-252.
56. Meiser BM, Wenke K, Thiery J, Wolf S, Devens C, Seidel D, Hammer C, Billingham ME, Reichart B: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993, 25:2077-2079.
57. Vincent TS, Wulfert E, Merler E: Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys Res Commun 1991, 180:1284-1289.
58. Park J-W, Merz M, Braun P: Regression of transplant coronary artery disease during chronic LDL-apheresis. J Heart Lung Transplant, in press. Small, nonrandomized trial that showed that aggressive lipid-lowering therapy with pravastatin and LDL apheresis induced regression of transplant CAD as assessed by quantitative angiography.
59. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
60. Gotto AM Jr: Lipid lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation 1995, 92:646-656.
61. Norman DJ, Illingworth DR, Munson J, Hosenpud J: Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [letter]. N Engl J Med 1988, 318:46-47.
62. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, Brownfield E, Wilmarth J, Leonard L, Chuck C, et al.: Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990, 82:IV-281-IV-283.
63. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991, 151:43-49.
64. Kuo PC, Kirshenbaum JM, Gordon J, Laffel G, Young P, DiSesa VJ, Mudge GH Jr, Vaughan DE: Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989, 64:631-635.
65. Peters JR, Kubo SH, Olivari MT, Knutson KR, Hunninghake DB: Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin. Am J Cardiol 1993, 71:1485-1488.
66. Anguita M, Alonso-Pulpon L, Arizon JM, Cavero MA, Valles F, Segovia J, Perez-Jimenez F, Crespo M, Concha M: Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery disease. Am J Cardiol 1994, 74:776-779.
67. Hidalgo L, Zambrana JL, Blanco-Molina A, Lopez-Granados A, Concha M, Casares J, Jimenez-Perez J, Lopez-Miranda J, Perez-Jimenez F: Lovastatin versus bezafibrate for hyperlipidemia treatment after heart transplantation. J Heart Lung Transplant 1995, 14:461-467.
68. Barbir M, Rose M, Kushwaha S, Akl S, Mitchell A, Yacoub M: Low-dose simvastatin for the treatment of hypercholesterolemia in recipients of cardiac transplantation. Int J Cardiol 1991, 33:241-246.
69. Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, De Geest H: Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994, 58:42-45.
70. Campana C, Iacona I, Regazzi MB, Gavazzi A, Peram G, Raddato V, Montemartini C, Vigano M: Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995, 29:235-239.
71. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ: Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995, 14:613-622.
72. Ballantyne CM, Bourge RC, Leslie DJ, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Radovancevic B, Taylor DO, Ventura HO, et al.: Safety and tolerability of lipid lowering drugs after heart transplantation: the Heart Transplant Lipid Registry [abstract]. Circulation 1996, 94:I-289.
73. Regazzi MB, Iacona I, Campana C, Gavazzi A, Vigano M, Peram G: Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994, 26:2644-2645.
74. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, MacDonald JS: HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991, 257:1225-1235.
75. Goldberg RB, Roth D: A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995, 76:107A-109A.
76. Henkin Y, Oberman A, Hurst DC, Segrest JP: Niacin revisited: clinical observations on an important but underutilized drug. Am J Med 1991, 91:239-246.
77. van der Heide JJH, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM: Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993, 329:769-773.
78. Grimminger F, Grimm H, Führer D, Papavassilis C, Lindemann G, Blecher C, Mayer K, Tabesch F, Krämer H-J, Stevens J, Seeger W: ω-3 Lipid infusion in a heart allotransplant model: shift in fatty acid and lipid mediator profiles and prolongation of transplant survival. Circulation 1996, 93:365-371.
79. Ballantyne CM, Bourge RC, Domalik LJ, Eisen HJ, Fishbein DP, Kubo SH, Lake KD, Radovancevic B, Taylor DO, Ventura HO, et al.: Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 1996, 78:532-535.